Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31414869 | 0.91 | POLB (0.46) | POLBALDH1A1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL10304450 | 0.78 | POLB (0.62) | POLBALDH1A1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL11808078 | 0.78 | KMT2A (0.63) | POLBALDH1A1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL11684372 | 0.76 | POLB (0.51) | POLBALDH1A1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL11774212 | 0.76 | POLB (0.59) | POLBALDH1A1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL16588002 | 0.76 | POLB (0.61) | POLBALDH1A1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL11648474 | 0.75 | LMNA (0.60) | POLBALDH1A1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL15333089 | 0.75 | POLB (0.73) | POLBALDH1A1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL19002339 | 0.75 | LMNA (0.60) | POLBALDH1A1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL2561521 | 0.75 | POLB (0.73) | POLBALDH1A1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148390-B2 | Monocyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme, Corp. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148390-B2 | Monocyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme, Corp. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100152216-A1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-17 | — | — | US | disclosed |
| US-20100152216-A1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-17 | — | — | US | disclosed |
| WO-2008112159-A2 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152216-A1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | POLB 4249/4885ALDH1A1 843/4885KMT2A 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.